

Tania Crombet Ramos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3616940/tania-crombet-ramos-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

2,111
citations

23
h-index

45
g-index

80
ext. papers

2,409
ext. citations

4.8
avg, IF

4.18
L-index

#	Paper	IF	Citations
73	Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.. <i>Frontiers in Oncology</i> , 2022 , 12, 823287	5.3	0
72	Pulmonary Thrombosis in COVID-19 Treated by Thrombolysis: A Small Case Series Using Streptokinase. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 431-435	5.3	2
71	An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases. <i>Immunotherapy</i> , 2021 , 13, 289-295	3.8	2
70	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 639745	5.3	2
69	Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1735-1743	7.4	5
68	Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. <i>Frontiers in Oncology</i> , 2020 , 10, 817	5.3	8
67	Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. <i>Oncolimmunology</i> , 2020 , 9, 1762465	7.2	4
66	Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. <i>Revista Bionatura</i> , 2020 , 5, 1056-1062	0.3	
65	Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. <i>Clinical and Translational Immunology</i> , 2020 , 9, e1218	6.8	5
64	An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. <i>Immunity and Ageing</i> , 2020 , 17, 34	9.7	7
63	Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer. <i>Quality of Life Research</i> , 2020 , 29, 3441-3448	3.7	
62	COVID-19 and Cancer in Cuba. <i>Seminars in Oncology</i> , 2020 , 47, 328-329	5.5	3
61	Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. <i>Gerontology</i> , 2020 , 66, 553-561	5.5	12
60	Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients. <i>BMC Cancer</i> , 2020 , 20, 772	4.8	3
59	Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. <i>Experimental Gerontology</i> , 2019 , 124, 110633	4.5	7
58	CIMAvax-EGF: Toward long-term survival of advanced NSCLC. <i>Seminars in Oncology</i> , 2018 , 45, 34-40	5.5	10
57	Nimotuzumab: beyond the EGFR signaling cascade inhibition. <i>Seminars in Oncology</i> , 2018 , 45, 18-26	5.5	28

56	Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. <i>Seminars in Oncology</i> , 2018 , 45, 52-57	5.5	3
55	Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy. <i>Journal of Immunotherapy</i> , 2017 , 40, 289-301	5	4
54	Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. <i>Frontiers in Pharmacology</i> , 2017 , 8, 263	5.6	7
53	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. <i>Frontiers in Pharmacology</i> , 2017 , 8, 382	5.6	21
52	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2017 , 8, 269	8.4	34
51	Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15787-e15787	2.2	
50	Immunotherapy for Transforming Advanced Cancer into a Chronic Disease: How Far Are We? 2016 , 105-120		
49	Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 37-45	7.4	38
48	Immunoscintigraphy With ^{99m} Tc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016 , 41, 244-6	1.7	3
47	A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 3782-90	12.9	74
46	P2.40: CIMAvaxEGF Vaccine for the Treatment of Real-World NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S242	8.9	2
45	A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 684-9	4.6	20
44	CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. <i>Expert Review of Vaccines</i> , 2015 , 14, 1303-11	5.2	19
43	Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014 , 29, 173-8	3.9	8
42	Nimotuzumab: A Humanized Anti-EGFR Antibody 2014 , 1679-1694		
41	Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 737-47	7.4	7
40	A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2014 , 20, 3660-71	12.9	90
39	Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. <i>Cancer Biology and Therapy</i> , 2014 , 15, 504-9	4.6	28

38	Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data. <i>BMC Cancer</i> , 2014 , 14, 933	4.8	9
37	RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3111-TPS3111	2.2	
36	Immunosenescence and gender: a study in healthy Cubans. <i>Immunity and Ageing</i> , 2013 , 10, 16	9.7	14
35	Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. <i>BMC Cancer</i> , 2013 , 13, 299	4.8	49
34	Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience. <i>MAbs</i> , 2013 , 5, 202-7	6.6	19
33	A view on EGFR-targeted therapies from the oncogene-addiction perspective. <i>Frontiers in Pharmacology</i> , 2013 , 4, 53	5.6	29
32	Active immunotherapy in patients with progressive disease (PD) after first-line therapy: Racotumomab experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3086-3086	2.2	1
31	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. <i>Journal of Cancer Therapy</i> , 2013 , 04, 59-75	0.2	1
30	Trial proactive: A prospective, randomized, multicenter, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3123-TPS3123	2.2	
29	EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3013-3013	2.2	
28	Del nuevo producto biológico para el cáncer al impacto en la salud poblacional. <i>Revista Cubana De Salud Publica</i> , 2012 , 38, 781-793		
27	Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. <i>Cancer Biology and Therapy</i> , 2012 , 13, 600-5	4.6	49
26	Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2515-2515	2.2	
25	EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2527-2527	2.2	
24	Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 337-42	3.8	2
23	Control of advanced cancer: the road to chronicity. <i>International Journal of Environmental Research and Public Health</i> , 2011 , 8, 683-97	4.6	25
22	Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. <i>Journal of Immune Based Therapies and Vaccines</i> , 2011 , 9, 7		22
21	Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. <i>Cancer Biology and Therapy</i> , 2011 , 11, 373-82	4.6	105

20	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. <i>Cancers</i> , 2011 , 3, 2014-31	6.6	23
19	Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. <i>Clinical Cancer Research</i> , 2010 , 16, 2474-82	12.9	51
18	Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. <i>Cancer Biology and Therapy</i> , 2010 , 9, 343-9	4.6	114
17	Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.. <i>Hum Vaccin</i> , 2010 , 6, 736-744		27
16	Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. <i>Hum Vaccin</i> , 2010 , 6,		22
15	Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. <i>MAbs</i> , 2009 , 1, 41-8	6.6	158
14	Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. <i>Journal of Immunotherapy</i> , 2009 , 32, 92-9	5	44
13	Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. <i>Clinical Cancer Research</i> , 2008 , 14, 840-6	12.9	85
12	Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1452-8	2.2	158
11	Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. <i>Hum Vaccin</i> , 2007 , 3, 8-13		54
10	Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody Nimotuzumab. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1390-5	4.6	22
9	Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. <i>Cancer Biology and Therapy</i> , 2006 , 5, 145-9	4.6	44
8	Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. <i>Cancer Biology and Therapy</i> , 2006 , 5, 375-9	4.6	125
7	Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with ^{99m} Tc in patients with tumour of epithelial origin. <i>Nuclear Medicine Communications</i> , 2005 , 26, 1049-57	1.6	22
6	Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1646-54	2.2	232
5	Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal for EGF/r3 antibody. <i>European Journal of Pharmaceutical Sciences</i> , 2004 , 21, 261-70	5.1	13
4	Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. <i>Journal of Immunotherapy</i> , 2003 , 26, 139-48	5	91
3	Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. <i>Annals of Medicine</i> , 2003 , 35, 327-36	1.5	22

2	Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001 , 16, 93-102	3.9	19
1	Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19		4